Search Results for "Canasa"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Canasa. Results 1 to 4 of 4 total matches.
See also: mesalamine
Budesonide Rectal Foam (Uceris) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Nov 09, 2015 (Issue 1481)
(Cortifoam) and mesalamine rectal suppositories
(Canasa) are better tolerated, but their activity ...
The FDA has approved a rectal foam formulation of
the corticosteroid budesonide (Uceris - Salix/Valeant)
for induction of remission in patients with active mild
to moderate distal ulcerative colitis (UC) extending
up to 40 cm from the anal verge. Budesonide is also
available as oral extended-release tablets (also
branded as Uceris) for use in patients with UC and as
oral enteric-coated tablets (Entocort EC, and generics)
for treatment of Crohn's disease.
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
)
generic
Canasa (Allergan)
4 g/60 mL enema
1000 mg rectal
suppository
Induction: 4 g rectally once/day ...
View the Table: Some Drugs for Inflammatory Bowel Disease
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e115-9 doi:10.58347/tml.2023.1680d | Show Introduction Hide Introduction
Once-Daily Mesalamine (Lialda) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Mar 26, 2007 (Issue 1257)
is also available as an enema (Rowasa, and others)
and as a rectal suppository (Canasa).
The Multi ...
A once-daily oral formulation of mesalamine (Lialda - Shire) was recently approved by the FDA for induction of remission in patients with mild to moderate ulcerative colitis.
Drugs for Inflammatory Bowel Disease
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
mg rectal suppository Induction and maintenance: 1000 mg rectally 224.10
Canasa (Abbvie) once/day ...
Ulcerative colitis (UC) and Crohn's disease (CD),
referred to collectively as inflammatory bowel disease
(IBD), are chronic immune-mediated inflammatory
conditions. Guidelines for treatment of UC and CD
have been updated in recent years
Med Lett Drugs Ther. 2023 Jul 10;65(1680):105-12 doi:10.58347/tml.2023.1680a | Show Introduction Hide Introduction